BioXcel Therapeutics Past Earnings Performance
Past criteria checks 0/6
BioXcel Therapeutics's earnings have been declining at an average annual rate of -39.1%, while the Biotechs industry saw earnings growing at 12.3% annually. Revenues have been growing at an average rate of 92.5% per year.
Key information
-39.1%
Earnings growth rate
-28.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 92.5% |
| Return on equity | n/a |
| Net Margin | -12,974.9% |
| Next Earnings Update | 09 May 2024 |
Recent past performance updates
Recent updates
BioXcel Therapeutics: Igalmi's Commercial Uncertainty Remains, Downgrading To A Hold
Aug 28BioXcel Therapeutics Q2 2022 Earnings Preview
Aug 08BioXcel Therapeutics: BXCL501 For Acute Agitation In Patients With Dementia And Alzheimer's - A Great Asset
Jul 19BioXcel's Igalmi: Potential Market For Acute Agitation In Esquizofrenia And Bipolar Patients
May 18Revenue & Expenses BreakdownBeta
How BioXcel Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1 | -179 | 83 | 84 |
| 30 Sep 23 | 1 | -212 | 95 | 106 |
| 30 Jun 23 | 1 | -203 | 87 | 109 |
| 31 Mar 23 | 1 | -187 | 80 | 100 |
| 31 Dec 22 | 0 | -166 | 69 | 91 |
| 30 Sep 22 | 0 | -137 | 62 | 71 |
| 30 Jun 22 | 0 | -122 | 60 | 61 |
| 31 Mar 22 | 0 | -112 | 56 | 56 |
| 31 Dec 21 | 0 | -107 | 55 | 52 |
| 30 Sep 21 | 0 | -102 | 52 | 51 |
| 30 Jun 21 | 0 | -100 | 44 | 80 |
| 31 Mar 21 | 0 | -94 | 34 | 60 |
| 31 Dec 20 | 0 | -82 | 25 | 58 |
| 30 Sep 20 | 0 | -69 | 16 | 53 |
| 30 Jun 20 | 0 | -54 | 10 | 19 |
| 31 Mar 20 | 0 | -41 | 9 | 32 |
| 31 Dec 19 | 0 | -33 | 8 | 26 |
| 30 Sep 19 | 0 | -32 | 7 | 25 |
| 30 Jun 19 | 0 | -28 | 6 | 22 |
| 31 Mar 19 | 0 | -22 | 6 | 17 |
| 31 Dec 18 | 0 | -19 | 5 | 15 |
| 30 Sep 18 | 0 | -15 | 5 | 10 |
| 30 Jun 18 | 0 | -11 | 4 | 7 |
| 31 Mar 18 | 0 | -8 | 3 | 5 |
| 31 Dec 17 | 0 | -5 | 2 | 3 |
Quality Earnings: BTAI is currently unprofitable.
Growing Profit Margin: BTAI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BTAI is unprofitable, and losses have increased over the past 5 years at a rate of 39.1% per year.
Accelerating Growth: Unable to compare BTAI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BTAI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: BTAI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.